Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

OBJECTIVE: The aim of this study was to assess the safety and efficacy of extending bevacizumab therapy beyond 15 months in nonprogressive ovarian cancer. PATIENTS AND METHODS: In this multinational prospective single-arm study (ClinicalTrials.gov NCT01239732), eligible patients had International Fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Oza, Amit M., Selle, Frédéric, Davidenko, Irina, Korach, Jacob, Mendiola, Cesar, Pautier, Patricia, Chmielowska, Ewa, Bamias, Aristotelis, DeCensi, Andrea, Zvirbule, Zanete, González-Martín, Antonio, Hegg, Roberto, Joly, Florence, Zamagni, Claudio, Gadducci, Angiolo, Martin, Nicolas, Robb, Stephen, Colombo, Nicoletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Ovarian Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181120/
https://www.ncbi.nlm.nih.gov/pubmed/27749456
http://dx.doi.org/10.1097/IGC.0000000000000836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181120/
https://www.ncbi.nlm.nih.gov/pubmed/27749456
http://dx.doi.org/10.1097/IGC.0000000000000836

Ejemplares similares